Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H11NO5S |
Molecular Weight | 233.242 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
InChI
InChIKey=FKENQMMABCRJMK-RITPCOANSA-N
InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://en.wikipedia.org/wiki/Sulbactam
http://www.drugbank.ca/drugs/DB09324
Curator's Comment: description was created based on several sources, including
https://en.wikipedia.org/wiki/Sulbactam
http://www.drugbank.ca/drugs/DB09324
Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics. Sulbactam in combination with semisynthetic antibiotic ampicillin sodium is indicated for the treatment of infections due to susceptible strains of the designated microorganisms: Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli etc; Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. Pneumoniae) tec; Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P62593 Gene ID: 10076131|||10076142|||13876868|||13877052|||13903673|||13905334|||13905363|||13906404|||13906709|||13906924|||13909533|||13909568|||14612524|||17824300|||17824435|||18157686|||20466965|||20466993|||20467118|||20468340|||20471961|||20491414|||20491639|||20492529|||20492626|||20493584|||2716540|||3244915|||3722457|||4924718|||5961992|||6276043|||8319064|||8319163|||9537966|||9538101|||9846067 Gene Symbol: bla|||blaT-3|||blaT-4|||blaT-5|||blaT-6 Target Organism: Escherichia coli |
0.062 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseUNASYN is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.36 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
83.79 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
1 g 1 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g 1 times / day steady-state, intravenous dose: 0.5 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.33 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
1 g 1 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g 1 times / day steady-state, intravenous dose: 0.5 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1 h |
SULBACTAM serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
SULBACTAM serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g 3 times / day multiple, intravenous Highest studied dose Dose: 4 g, 3 times / day Route: intravenous Route: multiple Dose: 4 g, 3 times / day Sources: |
unhealthy |
|
2 g 2 times / day multiple, intravenous Recommended Dose: 2 g, 2 times / day Route: intravenous Route: multiple Dose: 2 g, 2 times / day Sources: |
unhealthy |
PubMed
Title | Date | PubMed |
---|---|---|
Antibiotic susceptibility, serum response and surface properties of Klebsiella species. | 2001 |
|
Effect of granulocyte-macrophage colony-stimulating factor on treatment of acute osteomyelitis. An experimental investigation in rats. | 2001 |
|
[Fundamental and clinical studies on beta-lactamase inhibitors]. | 2001 Apr |
|
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. | 2001 Apr |
|
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms. | 2001 Aug |
|
[Guideline of antimicrobial therapy in the area of cardiovascular surgery]. | 2001 Dec |
|
Hepatotoxic reactions induced by beta-lactamase inhibitors. | 2001 Dec 17 |
|
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. | 2001 Feb |
|
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. | 2001 Feb |
|
Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. | 2001 Feb 13 |
|
Sepsis and multiple brain abscesses caused by Salmonella paratyphi B in an infant: successful treatment with sulbactam-ampicillin and surgical drainage. | 2001 Jan-Mar |
|
Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation. | 2001 Jul-Aug |
|
[Clinical analysis of neutropenic fever associated with hematological disorders]. | 2001 Mar |
|
An anaphylactic reaction possibly associated with an intraoperative coronary artery spasm during general anesthesia. | 2001 May |
|
Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. | 2001 Nov 1 |
|
The penetration of cefoperazone and sulbactam into the lumbar intervertebral discs. | 2001 Oct |
|
In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria. | 2001 Sep |
|
An unusual form of Actinomycosis of the mandible with a resultant gross sequester in a 4-year-old child: a case report. | 2001 Spring |
|
Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections. | 2002 |
|
Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis. | 2002 |
|
Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. | 2002 Apr |
|
[Acinetobacter, a nosocomial pathogen. Contribution of experimental models]. | 2002 Apr 13 |
|
Antimicrobial susceptibility of coagulase-negative staphylococci isolated from bovine mastitis in Argentina. | 2002 Aug |
|
Pharmacokinetics of an ampicillin/sulbactam (2:1) combination in rabbits. | 2002 Aug |
|
Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. | 2002 Aug |
|
Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. | 2002 Aug 14 |
|
Surveillance for antimicrobial resistance in Croatia. | 2002 Jan |
|
[A case of bronchopulmonary actinomycosis diagnosed by transbronchial biopsy of a bronchial polypoid tumor]. | 2002 Jun |
|
[Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999]. | 2002 Jun |
|
Prevalence of and resistance to anti-microbial drugs in selected microbial species isolated from bulk milk samples. | 2002 Jun |
|
Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients. | 2002 Jun |
|
CE versus LC for simultaneous determination of amoxicillin/clavulanic acid and ampicillin/sulbactam in pharmaceutical formulations for injections. | 2002 Jun 20 |
|
Low dose sultamicillin in acute sinusitis. | 2002 Mar |
|
The emergence of beta-lactamase resistance in respiratory pathogens. | 2002 Mar |
|
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). | 2002 Mar |
|
Bacteriology and antimicrobial susceptibility in biliary tract disease: an audit of 10-year's experience. | 2002 May |
|
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. | 2002 May |
|
Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors. | 2002 May 21 |
|
Reports of osteopenia/rickets of prematurity are on the increase because of improved survival rates of low birthweight infants. | 2002 Oct |
|
[The efficacy of prophylactic administration of SBT/ABPC for postoperative infection in neurosurgical operations]. | 2002 Oct |
|
Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics. | 2002 Oct |
|
The effect of high single dose parenteral vitamin A in addition to antibiotic therapy on healing of maxillary sinusitis in experimental acute sinusitis. | 2002 Sep 24 |
|
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests]. | 2003 |
|
Catalytic properties of an endogenous beta-lactamase responsible for the resistance of Azospirillum lipoferum to beta-lactam antibiotics. | 2003 Feb |
|
Current status of drug resistance among gram-negative bacilli isolated from admitted cases in a tertiary care centre. | 2003 Jan |
|
Acute otitis media and facial nerve paralysis in adults. | 2003 Jan |
|
Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. | 2003 Jan |
|
Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. | 2003 Jun 19 |
|
[beta-Lactamase-inhibitor combinations]. | 2003 Mar |
|
Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropics. | 2003 May 24 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: UNASYN should be administered by slow intravenous injection over at least 10–15 minutes or can also be delivered in greater dilutions with 50–100 mL of a compatible diluent as an intravenous infusion over 15–30 minutes.
The recommended adult dosage of UNASYN is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175930
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
||
|
LIVERTOX |
905
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
||
|
WHO-ATC |
J01CG01
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
||
|
NDF-RT |
N0000000202
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
||
|
WHO-VATC |
QJ01CG01
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
||
|
NCI_THESAURUS |
C260
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1623670
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
D013407
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
DTXSID1023605
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
68373-14-8
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
100000083256
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
CHEMBL403
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
Ampicillin and Sulbactam
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
269-878-2
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
10167
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | RxNorm | ||
|
SULBACTAM
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
C61957
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
9321
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
S4TF6I2330
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
2492
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
130313
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
S4TF6I2330
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
m10291
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB10676MIG
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
4845
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
DB09324
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY | |||
|
759886
Created by
admin on Wed Apr 02 09:08:42 GMT 2025 , Edited by admin on Wed Apr 02 09:08:42 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)